期刊文献+

Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new? 被引量:13

Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?
在线阅读 下载PDF
导出
摘要 AIM To review the conversion therapy for initially unre-sectable hepatocellular carcinoma(HCC) patients and the suitable timing for subsequent salvage surgery. METHODS A Pub Med search was undertaken from 1987 to 2017 to identify articles using the keywords including "unresectable" "hepatocellular carcinoma", "hepate-ctomy", "conversion therapy", "resection", "salvage surgery" and "downstaging". Additional studies were investigated through a manual search of the references from the articles. The exclusion criteria were duplicates, case reports, case series, videos, contents unrelated to the topic, comments, and editorial essays. The main and widely used conversion therapies and the suitable timing for subsequent salvage surgery were discussed in detail. Two members of our group independently performed the literature search and data extraction. RESULTS Liver volume measurements [future liver remnant(FLR)/total liver volume or residual liver volume/bodyweight ratio] and function tests(scoring systems and liver stiffness) were often performed in order to justify whether patients were suitable candidates for surgery. Successful conversion therapy was usually defined as downstaging the tumor, increasing FLR and providing subsequent salvage surgery, without increasing com-plications, morbidity or mortality. The requirementsfor performing salvage surgery after transcatheter arterial chemoembolization were the achievement of a partial remission in radiology, the disappearance of the portal vein thrombosis, and the lack of extrahepatic metastasis. Patients with a standardized FLR(sF LR) > 20% were good candidates for surgery after portal vein embolization, while other predictive parameters like growth rate, kinetic growth rate were treated as an effective supplementary. There was probably not enough evidence to provide a standard operation time after associating liver partition and portal vein ligation for staged hepatectomy or yttrium-90 microsphere radioembolization. The indications of any combinations of conversion therapies and the subsequent salvage surgery time still need to be carefully and comprehen-sively evaluated. CONCLUSION Conversion therapy is recommended for the treatment of initially unresectable HCC, and the suitable subse-quent salvage surgery time should be reappraised and is closely related to its previous therapeutic effect. AIM To review the conversion therapy for initially unre-sectable hepatocellular carcinoma(HCC) patients and the suitable timing for subsequent salvage surgery. METHODS A Pub Med search was undertaken from 1987 to 2017 to identify articles using the keywords including "unresectable" "hepatocellular carcinoma", "hepate-ctomy", "conversion therapy", "resection", "salvage surgery" and "downstaging". Additional studies were investigated through a manual search of the references from the articles. The exclusion criteria were duplicates, case reports, case series, videos, contents unrelated to the topic, comments, and editorial essays. The main and widely used conversion therapies and the suitable timing for subsequent salvage surgery were discussed in detail. Two members of our group independently performed the literature search and data extraction. RESULTS Liver volume measurements [future liver remnant(FLR)/total liver volume or residual liver volume/bodyweight ratio] and function tests(scoring systems and liver stiffness) were often performed in order to justify whether patients were suitable candidates for surgery. Successful conversion therapy was usually defined as downstaging the tumor, increasing FLR and providing subsequent salvage surgery, without increasing com-plications, morbidity or mortality. The requirementsfor performing salvage surgery after transcatheter arterial chemoembolization were the achievement of a partial remission in radiology, the disappearance of the portal vein thrombosis, and the lack of extrahepatic metastasis. Patients with a standardized FLR(sF LR) > 20% were good candidates for surgery after portal vein embolization, while other predictive parameters like growth rate, kinetic growth rate were treated as an effective supplementary. There was probably not enough evidence to provide a standard operation time after associating liver partition and portal vein ligation for staged hepatectomy or yttrium-90 microsphere radioembolization. The indications of any combinations of conversion therapies and the subsequent salvage surgery time still need to be carefully and comprehen-sively evaluated. CONCLUSION Conversion therapy is recommended for the treatment of initially unresectable HCC, and the suitable subse-quent salvage surgery time should be reappraised and is closely related to its previous therapeutic effect.
出处 《World Journal of Clinical Cases》 SCIE 2018年第9期259-273,共15页 世界临床病例杂志
关键词 UNRESECTABLE HEPATOCELLULAR carcinoma HEPATECTOMY Conversion therapy SALVAGE surgery DOWNSTAGING Unresectable Hepatocellular carcinoma Hepatectomy Conversion therapy Salvage surgery Downstaging
作者简介 Correspondence to:Wei-Hong Sha,MD,PhD,Professor,Chief,Department of Gastroenterology and Hepatology,Guangdong Geriatrics Institute,Guangdong General Hospital,Guangdong Academy of Medical Sciences,106 Zhongshan Second Road,Guangzhou 510080,Guangdong Province,China.syshaweihong@scut.edu.cn.Telephone:+86-20-83827812-61911,Fax:+86-20-83827812-61922.
  • 相关文献

参考文献5

二级参考文献93

  • 1林金芳,孙翠翔,郑怀美.Gonadotropin releasing hormone agonists and laparoscopy in the treatment of adenomyosis with infertility[J].Chinese Medical Journal,2000(5):58-61. 被引量:7
  • 2Funda Meric MD,Yehuda Z. Patt MD,Steve A. Curley MD,Judy Chase PharmD,Mark S. Roh MD,J. Nicolas Vauthey MD,Lee M. Ellis MD.Surgery After Downstaging of Unresectable Hepatic Tumors With Intra-Arterial Chemotherapy[J]. Annals of Surgical Oncology . 2000 (7)
  • 3Zhao-You Tang M.D.,Ye-Qin Yu M.D.,Xin-Da Zhou M.D.,Zeng-Chen MA M.D.,Ji-Zheu Lu M.D.,Zhi-Ying Lin M.D.,Kang-Da Liu M.D.,Sheng-Long Ye M.D.,Bing-Hui Yang M.D.,Hong-Wei Wang M.D.,Hui-Chuan Sun M.D..Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients[J]. World Journal of Surgery . 1995 (6)
  • 4Zhao-You Tang M.D.,Ye-Qin Yu M.D.,Xin-Da Zhou M.D.,Zeng-Chen Ma M.D.,Bing-Hui Yang M.D.,Zhi-Ying Lin M.D.,Ji-Zhen Lu M.D.,Kang-Da Liu M.D.,Zeng Fan M.D.,Zhao-Chong Zeng M.D..Treatment of unresectable primary liver cancer: With reference to cytoreduction and sequential resection[J]. World Journal of Surgery . 1995 (1)
  • 5Brans B,De Winter F,Defreyne L,Troisi R,Vanlangenhove P,Van Vlierberghe H, et al.The anti-tumoral activity of neo- adjuvant intra-arterial 131 I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biotherapy and Radiopharmaceuticals . 2001
  • 6Majno PE,Adam R,Bismuth H,Castaing D,Ariche A,Krissat J, et al.Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepato- cellular carcinoma in patients with cirrhosis. Annals of Surgery . 1997
  • 7Patt YZ,Hassan MM,Lozano RD,Brown TD,Vauthey JN,Curley SA, et al.Phase II trial of systemic continuous fluorou- racil and subcutaneous recombinant interferon Alfa-2b for treat- ment of hepatocellular carcinoma. Journal of Clinical Oncology . 2003
  • 8Sitzmann JV,Abrams R.Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Annals of Surgery . 1993
  • 9Tang ZY,Yu YQ.Long-term survival of hepatocellular carci- noma with reference to the role of early resection, multiopera- tion and multimodality treatment. Gann Monograph on Cancer Research . 1986
  • 10Tang ZY,Yu YQ,Zhou XD,Ma ZC,Lu JZ,Liu KD, et al.Cytoreduction and sequential resection; A hope for unre- sectable primary liver cancer. Journal of Surgical Oncology . 1991

共引文献128

同被引文献105

引证文献13

二级引证文献169

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部